ArticleHaematologica2026
Neurodegenerative Langerhans cell histiocytosis: long-term follow-up of 63 patients from the Italian Registry.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impulsivity, Compulsivity, Social Inappropriateness, and Other Neuropsychiatric Features in Cerebellar Histiocytosis.Cerebellum (London, England) · 2026Pooled it
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis.HemaSphere · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative Langerhans cell histiocytosis (ND-LCH) is a potentially devastating complication of LCH. We analyzed the natural history and the long-term outcome of patients with ND-LCH enrolled in the Italian LCH registry. ND-LCH was diagnosed in 63 of 637 patients with LCH (10%). Overall, at ND-LCH diagnosis 60% (38/63) patients were asymptomatic, 24% (15/63) had mild clinical manifestations including abnormal neurological examination and/or evoked potentials, and 16% (10/63) had overt symptoms. Brain magnetic resonance imaging (MRI) showed progressive structural changes in 13 of 63 (21%) patients over a median time of 1.5 years. Clinical ND-LCH developed after a median of 2.5 years since ND-LCH diagnosis. Thirty of 63 patients (17 pauci-symptomatic, 11 symptomatic, two asymptomatic but with severe brain MRI) received treatment, and 17 of 30 (57%) were stable or improved at the last follow-up). Thirty-three of 63 patients (mostly asymptomatic) were not treated and 31 of 33 (94%) remained stable through follow-up. At univariable analysis, the risk of developing overt clinical symptoms increased with LCH reactivations (odds ratio [OR]=6.40; P=0.018), severe brain MRI abnormalities at ND-LCH diagnosis (OR=10.40; P<0.001), and MRI findings worsening during follow-up (OR=10.25; P=0.001). The association of overt neurodegeneration with reactivations and MRI findings worsening was confirmed at multivariable analysis (OR=8.15; P=0.040; and OR=7.31; P=0.034, respectively). In conclusion, asymptomatic patients presenting with mild radioneuroimaging lesions at ND-LCH onset remained stable during follow-up; conversely, a history of LCH reactivation and worsening of brain MRI findings were associated with the appearance of overt clinical symptoms. These results may lay the basis for patients selection for treatment and different monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.